)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Piramal Pharma (PPLPHARMA) investor relations material
Piramal Pharma Q1 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 25/26 earnings summary29 Jul, 2025
Executive summary
Q1 FY26 results were broadly in line with guidance, with sales lumpiness from CDMO contract timing and CHG order phasing; revenue from operations was ₹1,934 crore, down 1% YoY, and EBITDA declined 26% to ₹165 crore.
Adjusted for destocking in a large CDMO product, underlying revenue showed early double-digit YoY growth; base CDMO business delivered mid-teen growth and improved margins, mainly from overseas sites.
Consumer healthcare business grew 15% YoY, led by power brands and e-commerce; net profit rose 8% YoY, aided by lower interest and tax rates.
Maintained zero OAI status since 2011; successful US FDA inspections and approvals at key facilities.
Unaudited standalone and consolidated financial results for Q1 FY26 were approved and published as per regulatory requirements.
Financial highlights
CDMO revenue was ₹997 crore, a 6% YoY decline; excluding destocking, mid-teen growth achieved.
Consumer healthcare sales up 15% YoY, with power brands up 18% and e-commerce up 41%, now 23% of segment sales.
Net profit increased 8% YoY, supported by lower interest and effective tax rates; PAT after exceptional items was a loss of ₹82 crore, improving from a loss of ₹89 crore in Q1 FY25.
Standalone revenue for Q1 FY26 was ₹1,689.80 crore, up from ₹969.88 crore in Q1 FY25; standalone net profit was ₹277.27 crore, up from ₹85.27 crore.
Consolidated revenue for Q1 FY26 was ₹1,933.71 crore, slightly down from ₹1,951.14 crore in Q1 FY25; consolidated net loss was ₹81.70 crore.
Outlook and guidance
On track for FY26 guidance: mid-single-digit revenue growth, mid-teen EBITDA margin, and YoY net profit growth; H2 expected to be stronger, especially for CHG.
FY30 aspiration: over ₹2,000 crore revenue, 25% EBITDA margin, and high-teen growth; strategic goals target $1.2B CDMO, $600M CHG, $200M PCH revenue by FY2030.
Financial statements prepared in accordance with Indian Accounting Standards and reviewed by auditors, with no material misstatements.
What was the impact of supplier insolvency?
What intangible asset was impaired?
How many subsidiaries' results were not reviewed?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Piramal Pharma earnings date
Q2 25/2623 Oct, 2025
Next Piramal Pharma earnings date
Q2 25/2623 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Piramal Pharma Limited is an India-based pharmaceutical company engaged in the development, manufacturing, and distribution of pharmaceutical products and services. The company operates through three main segments: Contract Development and Manufacturing (CDMO), Complex Hospital Generics, and Consumer Healthcare. It serves global pharmaceutical and biotechnology companies with services including drug development, active pharmaceutical ingredient (API) production, and sterile manufacturing. Piramal Pharma also markets over-the-counter products and hospital-use medications. The company is headquartered in Mumbai, India, and its shares are listed on the NSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage